Deep Vein Thrombosis

1. Deep Vein Thrombosis DR. SRINIVAS RAJKUMAR THIRAVIARAJ

2. DVT is the formation of thrombus deep veins predominantly in the legs

3. Also • Upper Limb • Paget Schrotter Syndrome – Ax V Thrombosis • May Thurner Syndrome - LIV compression by RIA

4. contents • Importance • Anatomy • Pathophysiology • Risk Factors • Diagnosis • Management • Follow Up/ Complications • Prevention

5. Venous thromboembolism (VTE), • Deep venous thrombosis (DVT) and Pulmonary embolism (PE), One of the three major cardiovascular causes of death, along with myocardial infarction and stroke

6. PE – most common preventable cause of death among hospitalized patients. PE and DVT occurring after total hip or knee replacement are unacceptable "never events" and are no longer reimbursable.

7. The long-term effects of nonfatal VTE lower the quality of life. • Postphlebitic syndrome, which eventually occurs in more than one-half of DVT patients – No effective management possible

8. ANATOMY

9. PATHOPHYSIOLOGY • Virchow’s Triad • Venous Stasis • Hypercoagulabilty • Endothelial Damage

10. ACQUIRED RISK FACTORS • Older age • Major surgery and orthopedic surgery • Cancers, especially of the bone, ovary, brain, pancreas, and lymphomas • Inactivity and immobilization, as with orthopedic casts, sitting, travel, bed rest, and hospitalization • Pregnancy and the postpartum period • Antiphospholipid syndrome • Trauma, minor leg injury, and lower limb amputation • Previous VTE

11. Combined oral contraceptives • Hormonal replacement therapy • Central venous catheters • Inflammatory diseases/some autoimmune diseases • Nephrotic syndrome • Obesity • Infection • HIV • Polycythemia vera • Chemotherapy • Intravenous drug use

12. INHERITED • Antithrombin deficiency • Protein C deficiency • Protein S deficiency (type I) • Factor V Leiden • Prothrombin G20210A • Dysfibrinogenemia • Non-O blood type

13. OTHERS: • Low free protein S • Activated protein C resistance • High factor VIII levels • Hyperhomocysteinemia • High fibrinogen levels • High factor IX levels • High factor XI levels

14. DIAGNOSIS • Clinical Examination • Only 1/4th of DVT Produces Clinical Signs & Symptoms • Most important Physical Sign – Swelling of Limbs • Muscles Become Stiff & Hard – M/I than Tenderness

15. Homan’s Sign – Forcible Dorsiflexion • Moses Sign – Squeezing from side to side • May Dislodge the Clot & Increase PE Risk

17. Two-level DVT Wells score

21. The sensitivity of the d-dimer is >80% for DVT (including isolated calf DVT) and >95% for PE. • With Suspected DVT, Doppler/Duplex USG should be preferred to D-Dimer

22. COMPLICATIONS

24. postphlebitic syndrome • A late effect of DVT -occurs in more than one-half of DVT patients. • Causes the venous valves of the leg to become incompetent and exude interstitial fluid. • Chronic ankle or calf swelling and leg aching, especially after prolonged standing. • Severe postphlebitic syndrome causes skin ulceration, especially in the medial malleolus of the leg. There is no effective medical therapy for this condition.

25. DVT & CANCER

26. Patients undergoing surgery for cancer have a higher risk of postoperative deep vein thrombosis (DVT) than those having surgery for nonmalignant diseases. • Longer time to recover from Surgery & Additional Functional limitation due to cancer also increases the risk.

27. Tumors Strongly Associated With Thrombosis • Autopsy studies and retrospective reviews suggest that cancers of the pancreas, lung, and stomach, and adenocarcinomas of unknown primary, are most strongly associated with thrombosis, adding to the view that mucin-producing cancers are the most often associated with VTE.

28. Lung cancer accounted for 21% of cases • Colon cancer for 18%, and • Prostate cancer for 17%

29. NON PHARMACOLOGICAL MANAGEMENT • Leg Elevation • Ambulation • Fitted Graduated Compression Stockings Special Situations • IVC Filters • Embolectomy

31. Mini-UFH, mini-dose unfractionated heparin, 5000 units subcutaneously twice (less effective) or three times daily (more effective); LMWH, low-molecular-weight heparin, enoxaparin, 40 mg once daily, or dalteparin, 2500 or 5000 units once daily; • IPC, intermittent pneumatic compression devices.

32. Minimum distance of walking required daily to prevent venous thromboembolism was 398 m • Wayman Unit= 398m / 0.5 Miles

33. SURGICAL PROPHYLAXIS • Low Dose Prophylaxis – UFH 5000 Units Deep S.C 2hrs before 5000 Units 8-12 hrs thereafter as required

34. For Active Phlebitis • Medium Dose – 20,000 to 60,000 units per day For PTE High Dose-60,000 to 120,000 Units/Day

35. Weight Based Dosing Regimen • Initial Therapy • Bolus – 80 U/Kg • Infusion 18U/Kg/Hr • UFH

36. LMWH & Pentasaccharide • Enoxaparin 1mg/kg/sc q12h or 1.5mg/kg/24h • Tinzaparin 175 IU/Kg SC Daily • Dalteparin 200 Iu/Kg SC Daily • Fondaparinux 5.0 mg sc daily(50 kg) 7.5mg(50-100kg) 10 mg sc (100+kg)

37. To Continue Treatment ? Reversible risk factors – 3months Isolated Calf vein DVT – Serial Imaging 2 wks If Extension – Anticoagulation With Cancer, Decision to be Individualised Usually Active Cancer + DVT = 6 months Tx

38. It is ideal to continue OP treatment with LMWH as OD (Dalteparin 200 IU/Kg OD 1 m.o continue 150 IU/Kg for 5 months) Warfarin – INR 2.5(2-3) – Higher incidence of complications and futher VTE episodes compared to LMWH.